natgillin/translations-raw huggingface dataset:
Ritonavir reduces the breakdown of darunavir, increasing the levels of darunavir in the blood. 
Ritonavir upočasnjuje hitrost razgradnje darunavirja in s tem povečuje njegove ravni v krvi.
As for every medicine, the company provided studies on the quality of Darunavir Krka d.d. 
Kot to velja za vsako zdravilo, je družba zagotovila študije o kakovosti zdravila Darunavir Krka d.d.
Therefore, the Agency's view was that, as for Prezista, the benefit outweighs the identified risk. 
Zato je menila, da njegove koristi enako kot pri zdravilu Prezista odtehtajo znana tveganja.
The medicine is to be taken with low-dose ritonavir or, as an alternative in adults, with cobicistat and with other HIV medicines, and should be taken with food. 
se jemlje z nizkimi odmerki ritonavirja ali, kot druga možnost pri odraslih, s kobicistatom in drugimi zdravili za zdravljenje okužbe s HIV, jemati pa ga je treba sočasno s hrano.
can only be obtained with a prescription and treatment should be started by a healthcare professional who has experience in the management of HIV. 
je le na recept, zdravljenje z njim pa mora uvesti zdravnik specialist, ki ima izkušnje z zdravljenjem okužbe z virusom HIV.
What measures are being taken to ensure the safe and effective use of Darunavir Krka d.d. 
Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe zdravila Darunavir Krka d.d.
This is a summary of the European public assessment report (EPAR) for Darunavir Krka d.d. 
To je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo Darunavir Krka d.d.
What are the benefits and risks of Darunavir Krka d.d. 
Kakšne so koristi in tveganja, povezani z zdravilom Darunavir Krka d.d.
The active substance in Darunavir Krka d.d., darunavir, is a protease inhibitor. 
Zdravilna učinkovina zdravila Darunavir Krka d.d., darunavir, je zaviralec proteaze.
It is given with low-dose ritonavir or, in adults, with cobicistat. 
Daje se skupaj z nizkimi odmerki ritonavirja ali pri odraslih s kobicistatom.
on 18 January 2018. 
EMA/23183/2018
contains the active substance darunavir. 
vsebuje zdravilno učinkovino darunavir.
For more information about treatment with Darunavir Krka d.d., read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist. 
preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte z zdravnikom ali farmacevtom.
used? 
uporablja?
Darunavir Krka d.d., taken in combination with other HIV medicines, reduces the amount of HIV in the blood and keeps it at a low level. 
v kombinaciji z drugimi protivirusnimi zdravili zniža količino virusa HIV v krvi in jo vzdržuje na nizki ravni.
been studied? 
raziskano?
Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Darunavir Krka d.d. 
Priporočila in varnostni ukrepi, ki jih morajo za varno in učinkovito uporabo zdravila Darunavir Krka d.d.
has been shown to have comparable quality and to be bioequivalent to Prezista. 
primerljivo raven kakovosti kot referenčno zdravilo Prezista ter da mu je biološko enakovredno.
For practical information about using Darunavir Krka d.d., patients should read the package leaflet or contact their doctor or pharmacist. 
naj bolniki preberejo navodilo za uporabo ali se posvetujejo z zdravnikom ali farmacevtom.
Other information about Darunavir Krka d.d. 
Druge informacije o zdravilu Darunavir Krka d.d.
It is not intended to provide practical advice on how to use Darunavir Krka d.d. 
Povzetek ni namenjen zagotavljanju praktičnih nasvetov o njegovi uporabi.
have been included in the summary of product characteristics and the package leaflet. 
upoštevati zdravstveni delavci in bolniki, so vključeni v povzetek glavnih značilnosti zdravila in navodilo za njegovo uporabo.
work? 
deluje?
Why is Darunavir Krka d.d. 
Zakaj je bilo zdravilo Darunavir Krka d.d.
Because Darunavir Krka d.d. 
Ker je zdravilo Darunavir Krka d.d.
What is Darunavir Krka d.d. 
Kaj je zdravilo Darunavir Krka d.d.
How does Darunavir Krka d.d. 
Kako se zdravilo Darunavir Krka d.d.
The Agency recommended that Darunavir Krka d.d. 
Priporočila je, da se zdravilo Darunavir Krka d.d.
How is Darunavir Krka d.d. 
Kako je bilo zdravilo Darunavir Krka d.d.
List of the names, pharmaceutical form(s), strength(s) of the medicinal product(s), route(s) of administration, applicant(s) in the Member States 
Seznam imen, farmacevtskih oblik, jakosti zdravila, poti uporabe zdravila, predlagatelj v državah članicah na
Didanosine 250 mg gastroresistant capsules, hard 
Farmacevtska oblika Pot uporabe zdravila
Spain 
Ime
Italy 
Predlagatelj
Germany 
Jakost
Further information on Verzenios can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports. 
Nadaljnje informacije o zdravilu Verzenios so na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Verzenios is available as tablets (50 mg, 100 mg and 150 mg). 
Zdravilo Verzenios je na voljo v obliki tablet (50 mg, 100 mg in 150 mg).
What measures are being taken to ensure the safe and effective use of Verzenios? 
Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe zdravila Verzenios?
The European Medicines Agency decided that the benefits of Verzenios are greater than its risks and it can be authorised for use in the EU. 
Evropska agencija za zdravila je zaključila, da so koristi zdravila Verzenios večje od z njim povezanih tveganj in da se lahko odobri za uporabo v EU.
Regarding safety, the main risk is diarrhoea, which is considered manageable with dose reduction. 
Kar zadeva varnost, je glavno tveganje driska, ki se šteje za obvladljivo z zmanjšanjem odmerka.
Other information about Verzenios 
Druge informacije o zdravilu Verzenios
The dose should be reduced if the patient is also taking certain medicines called ‘CYP3A4 inhibitors'. 
Odmerek je treba zmanjšati, če bolnik jemlje nekatera zdravila, imenovana „zaviralci CYP3A4“.
Data were considered sufficient to conclude that Verzenios can be of benefit also in women who have not yet been through the menopause. 
Podatki so bili ocenjeni kot zadostni za zaključek, da je lahko zdravilo Verzenios koristno tudi pri ženskah, ki še niso preživele menopavze.
It is used together with a hormonal medicine, either an aromatase inhibitor or fulvestrant. 
Uporablja se skupaj s hormonskim zdravilom, bodisi zaviralcem aromataze bodisi fulvestrantom.
As for all medicines, data on the use of Verzenios are continuously monitored. 
Tako kot za vsako zdravilo se tudi podatki o uporabi zdravila Verzenios stalno spremljajo.
Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Verzenios have been included in the summary of product characteristics and the package leaflet. 
Priporočila in previdnostni ukrepi, ki jih morajo za varno in učinkovito uporabo zdravila Verzenios upoštevati zdravstveni delavci in bolniki, so vključeni v povzetek glavnih značilnosti zdravila in navodilo za uporabo.
What is Verzenios and what is it used for? 
Kaj je zdravilo Verzenios in za kaj se uporablja?
An overview of Verzenios and why it is authorised in the EU 
Pregled zdravila Verzenios in zakaj je odobreno v EU
Side effects reported with Verzenios are carefully evaluated and any necessary action taken to protect patients. 
Neželeni učinki, o katerih so poročali pri zdravilu Verzenios, se skrbno ovrednotijo in po potrebi se sprejmejo ukrepi za zaščito bolnikov.
What benefits of Verzenios have been shown in studies? 
Kakšne koristi zdravila Verzenios so se pokazale v študijah?
What are the risks associated with Verzenios? 
Kakšna tveganja so povezana z zdravilom Verzenios?
Verzenios is a cancer medicine used to treat women with breast cancer that is advanced or has spread to other parts of the body. 
Verzenios je zdravilo za zdravljenje raka, ki se uporablja za zdravljenje žensk z rakom dojke, ki je napredoval ali se je razširil v druge dele telesa.
Grapefruit juice should be avoided during treatment with Verzenios as it may affect the way the medicine is absorbed and broken down in the body. 
Soku grenivke se je med zdravljenjem z zdravilom Verzenios treba izogibati, saj lahko vpliva na to, kako se zdravilo absorbira in presnavlja v telesu.
Verzenios can only be used when the cancer cells have certain types of receptor (called hormone receptors) on their surface (HR-positive) and do not produce abnormally large quantities of another receptor called HER2 (HER2-negative). 
Zdravilo Verzenios se sme uporabljati le, če imajo rakave celice na površini nekatere vrste receptorjev (imenovanih hormonski receptorji - so HR-pozitivne) in ne proizvajajo nenormalno velikih količin receptorja, imenovanega HER2 (so HER2-negativne).
For more information about using Verzenios, see the package leaflet or contact your doctor or pharmacist. 
Za več informacij glede uporabe zdravila Verzenios glejte navodilo za uporabo ali se posvetujte z zdravnikom ali farmacevtom.
Why is Verzenios authorised in the EU? 
Zakaj je bilo zdravilo Verzenios odobreno v EU?
The most common side effects with Verzenios (which may affect more than 1 in 10 people) are diarrhoea, infections, neutropenia (low levels of neutrophils, a type of white blood cell), anaemia (low red blood cell counts), tiredness, nausea (feeling sick), vomiting and decreased appetite. 
Najpogostejši neželeni učinki zdravila Verzenios (ki se lahko pojavijo pri več kot 1 bolnici od 10) so driska, okužbe, nevtropenija (nizke vrednosti nevtrofilcev, vrste belih krvnih celic), anemija (nizka raven rdečih krvnih celic), utrujenost, navzeja (slabost), bruhanje in zmanjšan tek.
Verzenios can only be obtained with a prescription and treatment should be started and supervised by a doctor experienced in the use of cancer medicines. 
Predpisovanje in izdaja zdravila Verzenios je le na recept, zdravljenje pa mora začeti in nadzorovati zdravnik, ki ima izkušnje z uporabo zdravil za zdravljenje raka.
A third study, conducted in 132 women who had received previous cancer treatment, failed to demonstrate that Verzenios used on its own was of benefit in the treatment of HR-positive, HER2negative breast cancer that had started to spread. 
Tretja študija, izvedena pri 132 ženskah, ki so predhodno prejele zdravljenje proti raku, ni pokazala, da je zdravilo Verzenios kot samostojno zdravilo koristno pri zdravljenju HR-pozitivnega in HER2-negativnega raka dojke, ki se je začel širiti.
Two main studies, involving 1,162 women, mostly postmenopausal, with HR-positive, HER2-negative breast cancer that had started to spread, showed that Verzenios can prolong the time patients live without their disease getting worse (progression-free survival). 
Dve glavni študiji, v kateri je bilo vključenih 1 162 žensk, večinoma po menopavzi, s HR-pozitivnim in HER2-negativnim rakom dojke, ki se je začel širiti, sta pokazali, da lahko zdravilo Verzenios podaljša čas, ki ga bolnice preživijo, ne da bi se jim bolezen poslabšala (preživetje brez napredovanja bolezni).
Verzenios contains the active substance abemaciclib. 
Zdravilo Verzenios vsebuje učinkovino abemaciklib.
The active substance in Verzenios, abemaciclib, blocks the activity of enzymes known as cyclindependent kinases (CDK) 4 and 6, which play a key role in regulating the way cells grow and divide. 
Učinkovina v zdravilu Verzenios, abemaciklib, zavira dejavnost encimov, ki se imenujejo od ciklina odvisne kinaze (CDK) 4 in 6 in imajo ključno vlogo pri uravnavanju rasti in delitve celic.
In some cancers, including HR-positive breast cancer, the activity of CDK 4 and 6 is increased, which helps the cancer cells to multiply uncontrollably. 
Pri nekaterih vrstah raka, vključno s HR-pozitivnim rakom dojke, se dejavnost encimov CDK 4 in 6 poveča, zato se rakave celice lažje nenadzorovano razmnožujejo.
How does Verzenios work? 
Kako zdravilo Verzenios deluje?
For the full list of side effects and restrictions of Verzenios, see the package leaflet. 
Za celoten seznam neželenih učinkov in omejitev pri uporabi zdravila Verzenios glejte navodilo za uporabo.
In the second study women taking Verzenios and fulvestrant lived on average 16 months without their disease getting worse, compared with 9 months for women taking placebo and fulvestrant. 
Ženske, ki so jemale zdravilo Verzenios in fulvestrant, so živele povprečno 16 mesecev, ne da bi se jim bolezen poslabšala, v primerjavi z devetimi meseci pri ženskah, ki so jemale placebo in fulvestrant.
By blocking CDK4 and CDK6, Verzenios slows the growth of HR-positive breast cancer cells. 
Zdravilo Verzenios z zaviranjem encimov CDK4 in CDK6 upočasni rast HR-pozitivnih celic raka dojke.
In the first study women taking Verzenios and an aromatase inhibitor (letrozole or anastrozole) lived on average 28 months without their disease getting worse compared with 15 months for women taking placebo (a dummy treatment) and an aromatase inhibitor. 
V prvi študiji so ženske, ki so jemale zdravilo Verzenios in zaviralec aromataze (letrozol ali anastrozol), povprečno živele brez poslabšanja bolezni 28 mesecev, v primerjavi s 15 meseci pri ženskah, ki so jemale placebo (zdravilo brez učinkovine) in zaviralec aromataze.
Verzenios used with an aromatase inhibitor or fulvestrant increased the time it took for the disease to get worse in postmenopausal women with HR-positive and HER2-negative breast cancer that is advanced or metastatic. 
Zdravilo Verzenios v kombinaciji z zaviralcem aromataze ali fulvestrantom je pri ženskah po menopavzi s HR-pozitivnim in HER2-negativnim rakom dojke, ki je napredoval ali metastaziral, podaljšalo čas do poslabšanja bolezni.
How is Verzenios used? 
Kako se zdravilo Verzenios uporablja?
Treatment should continue for as long as the patient is benefitting from it and side effects are tolerable. 
Priporočeni odmerek je 150 mg dvakrat na dan. Zdravljenje je treba nadaljevati, dokler ima bolnik od njega korist, neželeni učinki pa so znosni.
Ref.: EMEA/350155/2009 EMEA/H/C/1015 
: EMEA/350155/2009 EMEA/H/C/1015
Other information about the vaccine: 
Druge informacije o cepivu:
This may help to protect against the disease caused by the virus. 
To lahko prispeva k obrambi pred boleznimi, ki jih ta virus povzroča.
This authorisation was based on the authorisation granted to Prepandrix in 2008 (‘informed consent'). 
To dovoljenje je temeljilo na dovoljenju, ki je bilo leta 2008 odobreno za zdravilo Prepandrix („z obveščenim soglasjem“).
The emulsion contains an ‘adjuvant' (a compound containing oil) to stimulate a better response. 
Emulzija vsebuje tudi „adjuvans“ (spojino, ki vsebuje olje) za stimulacijo boljšega odziva.
The Committee recommended that the vaccine be given marketing authorisation. 
Odbor je priporočil, da se za cepivo odobri dovoljenje za promet.
A further study looked at the immunogenicity of single or double doses of the vaccine in 437 people aged over 60 years. 
Dodatna študija je raziskovala imunogenost enojnih ali dvojnih odmerkov cepiva pri 437 osebah, starejših od 60 let.
These patients needed double doses of the vaccine for protection. 
Pri teh bolnikih so bili za zaščito potrebni dvojni odmerki.
What benefit has the vaccine shown during the studies? 
Kakšne koristi je cepivo izkazalo med študijami?
It contains parts of influenza (flu) viruses that have been inactivated (killed). 
Vsebuje dele virusov (gripe), ki so bili inaktivirani (uničeni).
Adults over 80 years of age may need a double dose of the vaccine (one injection into each shoulder) with a second double dose three weeks later. 
Pri odraslih, starejših od 80 let, bo morda potreben dvojni odmerek cepiva (ena injekcija v vsako ramo) z drugim dvojnim odmerkom po treh tednih.
This is a special type of vaccine that is intended to protect against a strain of flu that may cause a future pandemic. 
To je posebna vrsta cepiva, namenjena za zaščito proti sevu gripe, ki lahko povzroči pandemijo v prihodnosti.
In elderly people, single doses of this vaccine also met these criteria, except for in the small number of patients aged over 80 years who did not have any protection against the virus at the start of the study. 
Pri starejših osebah so enojni odmerki cepiva prav tako zadostili temu merilu razen pri majhnem številu bolnikov, starejših od 80 let, ki na začetku študije niso imeli razvite zaščite proti virusu.
At 21 days after the second injection, 84% of the people receiving the vaccine had levels of antibodies that would protect them against H5N1. 
21 dni po drugem injiciranju je imelo 84 % oseb, ki so prejele cepivo, koncentracijo protiteles, ki bi jih zaščitila proti H5N1.
What is the risk associated with the vaccine? 
Kakšna tveganja so povezana s cepivom?
According to criteria laid down by the Committee for Medicinal Products for Human Use (CHMP), a prepandemic vaccine needs to bring about protective levels of antibodies in at least 70% of people for it to be considered suitable. 
V skladu z merili, ki jih je določil Odbor za zdravila za uporabo v humani medicini (CHMP), mora prepandemično cepivo, da lahko velja kot primerno, zagotoviti zaščitno koncentracijo protiteles pri vsaj 70 % oseb.
Vaccines work by ‘teaching' the immune system (the body's natural defences) how to defend itself against a disease. 
Cepiva delujejo tako, da imunski sistem (naravni obrambni mehanizem telesa) „naučijo“, kako naj se brani proti bolezni.
The participants received two injections of the vaccine containing one of four different doses of haemagglutinin. 
Sodelujoči so prejeli dve injekciji cepiva, ki sta vsebovali enega od štirih različnih odmerkov hemaglutinina.
The vaccine contains a flu strain called ‘A/VietNam/1194/2004 NIBRG-14' (H5N1). 
Cepivo vsebuje sev gripe, imenovan „A/VietNam/1194/2004 NIBRG-14“ (H5N1).
The vaccine is given by injection into the shoulder muscle in two single doses, at least three weeks apart. 
Cepivo se daje z injiciranjem v ramensko mišico v dveh enojnih odmerkih v razmiku najmanj treh tednov.
The injections were given 21 days apart. 
Injekciji sta bili vbrizgani v razmiku 21 dni.
The main measures of effectiveness were the levels of antibodies against the flu virus in the blood at three different times: before vaccination, on the day of the second injection (day 21) and 21 days later (day 
Glavno merilo učinkovitosti je bila koncentracija protiteles proti virusu gripe v krvi v treh različnih obdobjih: pred cepljenjem, na dan prejema druge injekcije (21. dan) ter 21 dni kasneje (42. dan).
Before use, the vaccine is made up by mixing together a suspension that contains the virus particles with an emulsion. 
Pred uporabo se cepivo pripravi z mešanjem suspenzije, ki vsebuje delce cepiva, in emulzije.
The main study showed that the vaccine containing 3.75 micrograms of haemagglutinin and the adjuvant produced an antibody response that met these criteria. 
Glavna študija je pokazala, da cepivo, ki vsebuje 3,75 mikrograma hemaglutinina in adjuvans, povzroči odziv protiteles, ki zadovolji to merilo.
Health experts are concerned that a future flu pandemic could be caused by the H5N1 strain of the virus. 
Zdravstvene strokovnjake skrbi, da bi utegnil naslednjo pandemično gripo povzročiti sev virusa H5N1.
When a person is given the vaccine, the immune system recognises the virus as ‘foreign' and makes antibodies against it. 
Ko oseba prejme cepivo, imunski sistem prepozna virus kot „tujek“ in proti njemu razvije protitelesa.
The vaccine has been developed to provide protection against this strain, so that it can be used before or during a flu pandemic. 
Cepivo je bilo pripravljeno za zaščito proti temu sevu, tako da ga je mogoče uporabiti pred pandemijo gripe ali med njo.
For the full list of all side effects reported with the vaccine, see the Package Leaflet. 
Za celoten seznam neželenih učinkov, o katerih so poročali pri uporabi cepiva, glejte navodilo za uporabo.
The main study of the vaccine included 400 healthy adults aged between 18 and 60 years and compared the ability of different doses of the vaccine, with or without the adjuvant, to trigger the production of antibodies (‘immunogenicity'). 
V glavno študijo cepiva je bilo vključenih 400 zdravih odraslih, starih od 18 do 60 let, v njej pa so primerjali učinkovitost različnih odmerkov virusa, z adjuvansom ali brez njega, pri sprožanju tvorbe protiteles („imunogenost“).
The vaccine should not be given to people who have had an anaphylactic reaction (severe allergic reaction) to any of the components of the vaccine, or to any of the substances found at very low levels in the vaccine, such as eggs, chicken protein, ovalbumin (a protein in egg white), formaldehyde, gentamicin sulphate (an antibiotic) and sodium deoxycholate. 
Cepivo se ne sme dajati osebam, ki so imele anafilaktično reakcijo (resno alergijsko reakcijo) na katero koli sestavino cepiva ali na katero koli od snovi, ki se v sledeh (v zelo nizkih količinah) nahajajo v cepivu, kot so jajca, piščančje beljakovine, ovalbumin (beljakovina v beljaku), formaldehid, gentamicinijev sulfat (antibiotik) in natrijev deoksiholat.
A flu pandemic happens when a new strain of flu virus appears that can spread easily from person to person because people have no immunity (protection) against it. A pandemic can affect most countries and regions around the world. 
Pandemija gripe nastopi, ko se pojavi novi sev virusa gripe, ki se lahko brez težav širi s človeka na človeka, ker ljudje nanj niso imuni (zaščiteni proti njemu).
Why has the vaccine been approved? 
Zakaj je bilo cepivo odobreno?
The full EPAR for the vaccine can be found here. 
Celotno evropsko javno poročilo o oceni zdravila (EPAR) za cepivo je na voljo tukaj.
This vaccine contains small amounts of haemagglutinins (proteins from the surface) of the H5N1 virus. 
To cepivo vsebuje majhno količino hemaglutininov (beljakovin s površine) virusa H5N1.
What is the vaccine used for? 
Za kaj se cepivo uporablja?
The most common side effects with Prepandemic Influenza Vaccine (H5N1) (Split Virion, Inactivated, Adjuvanted) GlaxoSmithKline Biologicals (seen with more than 1 in 10 doses of the vaccine) are headache, arthralgia (joint pain), myalgia (muscle pain), reactions at the site of the injection (hardening, swelling, pain and redness), fever and fatigue (tiredness). 
Najpogostejši neželeni učinki prepandemičnega cepiva proti gripi (H5N1) (z delci virionov, inaktiviranega, z adjuvansom) Glaxosmithkline Biologicals (ki so se pojavili pri 1 od 10 odmerkov cepiva) so glavobol, artralgija (bolečine v sklepih), mialgija (bolečine v mišicah), reakcije na mestu injiciranja (zatrdlina, oteklina, bolečina, rdečina), povišana telesna temperatura in utrujenost.
Prepandemic Influenza Vaccine (H5N1) (Split Virion, Inactivated, Adjuvanted) GlaxoSmithKline Biologicals prepandemic influenza vaccine (H5N1) (split virion, inactivated, adjuvanted) (A/VietNam/1194/2004 NIBRG-14) 
Prepandemično cepivo proti gripi (H5N1) (z delci virionov, inaktivirano, z adjuvansom) GlaxoSmithKline Biologicals cepivo proti pandemiji gripe (H5N1) (z delci virionov, inaktivirano, z adjuvansom) (A/Vietnam/1194/2004 (NIBRG-14)
How has the vaccine been studied? 
Kako je bilo cepivo raziskano?
Vaccination should be delayed in people who have a sudden fever. 
Pri osebah, ki imajo nenadno povišano telesno temperaturo, je treba cepljenje odložiti.
The European Commission granted a marketing authorisation valid throughout the EU for Prepandemic Influenza Vaccine (H5N1) (Split Virion, Inactivated, Adjuvanted) GlaxoSmithKline Biologicals to GlaxoSmithKline Biologicals S.A. on 26 September 2008. 
Evropska komisija je dovoljenje za promet z zdravilom, veljavno po vsej EU za zdravilo Prepandemično cepivo proti gripi (H5N1) (z delci virionov, inaktivirano, z adjuvansom) odobrila družbi GlaxoSmithKline Biologicals S.A. dne 26. septembra 2008.
How does the vaccine work? 
Kako cepivo deluje?
How is the vaccine used? 
Kako se cepivo uporablja?
What is Prepandemic Influenza Vaccine (H5N1) (Split Virion, Inactivated, Adjuvanted) GlaxoSmithKline Biologicals? 
Kaj je prepandemično cepivo proti gripi (H5N1) (z delci virionov, inaktivirano, z adjuvansom) GlaxoSmithKline Biologicals?